Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

Docetaxel is used as a standard treatment in patients with metastatic castration-resistant prostate cancer. However, a large subset of patients develops resistance. Understanding resistance mechanisms, which are largely unknown, will allow identification of predictive biomarkers and therapeutic targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Nakouzi, Nader, Cotteret, Sophie, Commo, Frédéric, Gaudin, Catherine, Rajpar, Shanna, Dessen, Philippe, Vielh, Philippe, Fizazi, Karim, Chauchereau, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996665/
https://www.ncbi.nlm.nih.gov/pubmed/24525428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996665/
https://www.ncbi.nlm.nih.gov/pubmed/24525428

Ejemplares similares